Premature termination codons (PTCs) account for 10 to 20% of genetic diseases in humans. The gene inactivation resulting from PTCs can be counteracted by the use of drugs stimulating PTC readthrough, thereby restoring production of the full-length protein. However, a greater chemical variety of readthrough inducers is required to broaden the medical applications of this therapeutic strategy.
View Article and Find Full Text PDFMultimed Tools Appl
February 2022
Glioma is one of the most important central nervous system tumors, ranked 15th in the most common cancer for men and women. Magnetic Resonance Imaging (MRI) represents a common tool for medical experts to the diagnosis of glioma. A set of multi-sequences from an MRI is selected according to the severity of the pathology.
View Article and Find Full Text PDFThe 2,5-Diketopiperazines (DKPs) constitute a large family of natural products with important biological activities. Bicyclomycin is a clinically-relevant DKP antibiotic that is the first and only member in a class known to target the bacterial transcription termination factor Rho. It derives from cyclo-(L-isoleucyl-L-leucyl) and has an unusual and highly oxidized bicyclic structure that is formed by an ether bridge between the hydroxylated terminal carbon atom of the isoleucine lateral chain and the alpha carbon of the leucine in the diketopiperazine ring.
View Article and Find Full Text PDFPremature termination codons (PTCs) are generally associated with severe forms of genetic diseases. Readthrough of in-frame PTCs using small molecules is a promising therapeutic approach. Nonetheless, the outcome of preclinical studies has been low and variable.
View Article and Find Full Text PDF